OB318
INDICATION
Hepatocellular Carinoma
Mechanism of Action
It is a first-in-class new drug with novel dual inhibitory functions in metastasis and angiogenesis against by its high selectivity in anti-cancer activity and efficacy against multiple cancer cell lines.
CURRENT STATUS
Phase 1 initated in taiwan
Efficacy
The administration of OB318 dramatically reduced tumor volume in xenograft mouse models including the hepatoma HepG2, Huh-7, prostate PC3, lung cancer A549 and melanoma B16F10 cells.
Market Potential
Million of patients with liver cancer die annually and Hepatocellular cancer (HCC) is the most common type of primary liver cancer, accounting for about 90 percent of cases. The currently available treatment options are with limited increase in overall survival and therefore new effective treatment is urgently required to meet the medicalneed for Hepatocellular Carinoma forecasted to be US$5bn in 2025 (Reference: Allied Market Research)